Provectus Biopharmaceuticals, Inc. CEO, director and 10% owner Edward Pershing reported a conversion on November 13, 2026: the 8% unsecured convertible promissory note automatically converted into 11,328 Series D-1 preferred shares at $2.862 per share, and those preferred shares converted into 113,280 common shares at 10 common shares per preferred share. His reported direct common-stock holdings after the transaction were 3,055,221 shares.
Provectus Biopharmaceuticals, Inc. reported a net loss of $1,273,710 for the quarter ended September 30, 2026, compared with $1,323,629 a year earlier; nine-month net loss was $3,563,375 versus $4,337,312. It reported no revenue from product sales or commercial operations. Nine-month grant revenue was $0, down from $336,108, while operating cash use was $1,575,409 versus $2,456,438.
Cash was $180,733 at September 30, 2026, and the working capital deficit was $6,730,268, compared with $251,291 and $6,329,504 at December 31, 2025. Management said its plans do not alleviate substantial doubt about the company’s ability to continue as a going concern within one year after the statements are issued; it plans to seek additional capital.
At September 30, $2,796,514 of principal and interest remained on 2025 Notes, which automatically convert into preferred stock at maturity. After quarter-end, $480,897 converted into 168,031 Series D-1 preferred shares at $2.862 per share.
Provectus Biopharmaceuticals, Inc. CEO, director and 10% owner Edward Pershing reported the conversion of an 8% unsecured convertible promissory note into 13,216 Series D-1 Convertible Preferred Stock shares on November 6, 2026, at a conversion price of $2.862 per share. Each preferred share is convertible into 10 common shares, representing 132,160 underlying common shares. The report lists 3,043,893 shares following the transaction.
Provectus Biopharmaceuticals, Inc. CEO, director and 10% owner Edward Pershing reported the conversion of his 8% unsecured convertible promissory note into 24,544 Series D-1 Convertible Preferred Stock shares on October 30, 2026, at $2.862 per share. The preferred shares are convertible into 245,440 common shares at 10 common shares per preferred share. His reported position following the transaction was 3,030,677 shares; no Rule 10b5-1 plan was reported.
Provectus Biopharmaceuticals (PVCT) reported that CEO, director and 10% owner Edward Pershing’s outstanding principal and interest under an 8% unsecured convertible promissory note automatically converted on October 23, 2026, into 7,599 Series D-1 Convertible Preferred Stock shares at $2.862 per share. Those 7,599 preferred shares converted into 75,990 common shares; Pershing’s reported common-stock holdings after the transactions were 3,006,133 shares.
Provectus Biopharmaceuticals, Inc. CEO Edward Pershing's outstanding principal and interest on an 8% unsecured convertible promissory note automatically converted on October 10, 2026, into 22,609 Series D-1 Convertible Preferred Stock shares at $2.862 per share. Each preferred share is convertible into 10 common shares. Pershing's reported direct holdings following the transaction were 2,998,534 preferred shares.
Provectus Biopharmaceuticals CEO and director Edward Pershing reported that an 8% unsecured convertible promissory note automatically converted on October 3, 2026, into 13,216 Series D-1 preferred shares at $2.862 per share. The preferred shares were converted into 132,160 common shares, bringing his reported direct common-stock holdings to 2,975,925 shares. Each preferred share is convertible into 10 common shares, and the preferred stock is scheduled to convert automatically on December 31, 2028, unless converted earlier. No Rule 10b5-1 plan is reported.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.
PROVECTUS BIOPHARMACEUTICALS, INC. (symbol: PVCT) is the issuer of record for a Form 4 filing submitted to the SEC.